000			01294 a2200349 4500
005			20250516003104.0
264		0	_c20110408
008			201104s 0 0 eng d
022			_a1476-5551
024	7		_a10.1038/leu.2010.215 _2doi
040			_aNLM _beng _cNLM
100	1		_aJabbour, E
245	0	0	_aManagement of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. _h[electronic resource]
260			_bLeukemia _cFeb 2011
300			_a201-10 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
650	0	4	_aBenzamides
650	0	4	_aDasatinib
650	0	4	_aDisease Management
650	0	4	_aHumans
650	0	4	_aImatinib Mesylate
650	0	4	_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xcomplications
650	0	4	_aPiperazines _xadverse effects
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aPyrimidines _xadverse effects
650	0	4	_aThiazoles _xadverse effects
700	1		_aDeininger, M
700	1		_aHochhaus, A
773	0		_tLeukemia _gvol. 25 _gno. 2 _gp. 201-10
856	4	0	_uhttps://doi.org/10.1038/leu.2010.215 _zAvailable from publisher's website
999			_c20191856 _d20191856